Infant cataracts no better with IOLs than contact lenses

Article

Online research in the Archives of Opthalmology has reported that contact lenses for infants who had undergone surgery for unilateral congenital cataracts resulted in similar visual outcomes for those who received an IOL implant.

Online research in the Archives of Opthalmology has reported that contact lenses for infants who had undergone surgery for unilateral congenital cataracts resulted in similar visual outcomes for those who received an IOL implant.

A total of 114 infants, aged between 1-6 months had cataract surgery and received either primary IOL implantation or contact lenses to correct aphakia. Visual acuity was then tested when the infants reached one year of age and no significant difference was found between the groups.

The authors, led by Dr Scott Lambert of Emory University in Atlanta wrote: “The theoretical long-term benefit of having the IOL in the capsular bag versus implanted in the ciliary sulcus as a secondary procedure cannot be quantified at this point. We suggest that practitioners continue to exercise caution when considering implanting IOLs in infants. The ultimate role for IOL implantation during infancy may be further clarified after a longer follow-up of these children.”

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.